Mefenamic Acid

Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Caution and personalized dose adjustment in patients with the following genotypes
  • Other genes that may be involved
  • Substrate of
  • Inhibits
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Parkemed; Cyprus: Aidol, Alfoxan, Ponstan; Finland: Ponstan; France: Ponstyl; Greece: Acinic, Aidol, Algopress, Calmin, Lavipon, Mefenamic Acid, Penta, Ponstan, Vidan; Hungary: Ponmel; Ireland: Mefac, Mefenamic Acid, Ponalgic, Ponstan; Italy: Lysalgo; Malta: Alfoxan, Ponstan; Poland: Antalv, Apo-Mefen, Mefacit; Portugal: Ponstan; Romania: Vidan; Spain: Coslan; UK: Ponstan.

North America

Canada: Mefenamic Acid; USA: Ponstel.

Latin America

Argentina: Ponstil Forte; Brazil: Ácido Mefenâmico, Ponsdril, Ponstan; Mexico: Artriden, Namifen, Ponstan.


Japan: Bafhameritin, Mefenamic Acid, Milrest, Mycasaal, Neuritorl, Onemeday, Pontal, Youfenam.

Drug combinations


Mefenamic Acid: C~15~H~15~NO~2~. Mw: 241.29. (1) Benzoic acid, 2-(2,3-dimethylphenyl)amino-; (2) N-2,3-Xylylanthranilic acid. CAS-61-68-7 (1962).

Pharmacologic Category

Analgesics and Antipyretics; Other Nonsteroidal Anti-inflammatory Agents. (ATC-Code: M01AG01).

Mechanism of action

Reversibly inhibits cyclooxygenase-1 and 2 (COX-1/PTGS1 and COX-2/PTGS2) enzymes, which results in decreased formation of prostaglandin precursors. Has antipyretic, analgesic, and anti-inflammatory properties.

Therapeutic use

Short-term relief of mild to moderate pain including primary dysmenorrhea.

Pregnancy and lactiation implications

Avoid use in 3^rd^ trimester due to possible premature closure of ductus arteriosus. Use not recommended while breast-feeding.

Unlabeled use


Hypersensitivity to mefenamic acid, aspirin, other NSAIDs, or any component of the formulation. Perioperative pain in setting of coronary artery bypass graft surgery. Active ulceration or chronic inflammation of gastrointestinal tract. Renal disease.

Warnings and precautions

Anaphylactoid reactions might occur (do not use in asthma, bronchospasm, rhinitis, or urticaria with NSAID or aspirin therapy). Platelet adhesion and aggregation may be decreased. Might prolong bleeding time. Anemia might occur. NSAIDs are associated with increased risk of adverse cardiovascular thrombotic events, including myocardial infarction, stroke, and new onset or worsening of pre-existing hypertension. NSAIDs may increase risk of gastrointestinal irritation, inflammation, ulceration, bleeding, and perforation (use caution with history of bleeding or ulcers, concurrent therapy with aspirin, anticoagulants and/or corticosteroids, smoking, use of alcohol, elderly or debilitated patients). NSAIDs might cause serious skin adverse events including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis. Do not administer in aspirin-sensitive asthma (severe bronchospasm might occur) and use caution in other forms of asthma. Use contraindicated for treatment of perioperative pain in setting of coronary artery bypass graft surgery. Use with caution in decreased hepatic function. The elderly are at increased risk for adverse effects (especially peptic ulceration, CNS effects, renal toxicity). Withhold prior to surgical or dental procedures. Use not recommended in pre-existing renal disease or substantial renal impairment.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart